Facial Plast Surg 2020; 36(02): 186-193
DOI: 10.1055/s-0040-1709126
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma

Authors

  • Vincent T. Ma

    1   Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
  • Catherine T. Haring

    2   Department of Otolaryngology- Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan
  • Govind Warrier

    1   Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
  • Paul L. Swiecicki

    1   Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    3   Department of Internal Medicine, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
15 May 2020 (online)

Preview

Abstract

Cutaneous squamous cell carcinoma (cSCC) and melanoma encompass the majority of all malignant skin cancers. There has been an increase in their incidence globally in recent decades. In cases of high-risk, unresectable, or metastatic disease; or when patient factors or preferences limit the availability of conventional surgery or radiotherapy; or a systemic therapy is often warranted. Our improved understanding of the molecular and immune pathogenesis underlying tumor growth and development has been critical in advancing cancer therapeutics. Over the past several years, several new systemic agents have been approved for both diseases. The role of cytotoxic chemotherapy is gradually waning with the introduction of targeted therapy and immunotherapy. In this article, we review the current and relevant literature and evidence of cytotoxic chemotherapy, targeted therapy, and immune checkpoint inhibitors in the adjuvant and neoadjuvant settings for cSCC and melanoma. Additionally, we describe their role in the unresectable or metastatic disease setting.

Drs. Ma and Haring contributed equally to the development of this manuscript.